Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors Jan-Paul BohnGeorg PallMichael Steurer Review Article 29 January 2016 Pages: 263 - 275
Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group Samantha C. SodergrenEllen CopsonColin D. Johnson Review Article 18 December 2015 Pages: 277 - 292
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer Fotios LoupakisAlexander SteinPia Ă–sterlund Review Article Open access 19 December 2015 Pages: 293 - 308
Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with Axitinib Satoshi ImaiHideaki MiyakeMasato Fujisawa Original Research Article 01 October 2015 Pages: 309 - 315
Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer John SarantopoulosMonica M. MitaLuis H. Camacho Original Research Article 27 October 2015 Pages: 317 - 327
Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents Hideaki MiyakeMototsugu MuramakiMasato Fujisawa Original Research Article 27 October 2015 Pages: 329 - 335
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer Filippo PietrantonioFilippo de BraudMaria Di Bartolomeo Original Research Article 04 November 2015 Pages: 337 - 343
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis Francesco MassariChiara CiccareseMatteo Brunelli Original Research Article 06 November 2015 Pages: 345 - 351
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells J. U. SchmohlM. K. GleasonD. A. Vallera Original Research Article 14 November 2015 Pages: 353 - 361
Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing Alexandre HarléPierre Filhine-TresarrieuJean-Louis Merlin Original Research Article 11 December 2015 Pages: 363 - 370
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status Florence HuguetMarie FernetAnnette K. Larsen Original Research Article 15 December 2015 Pages: 371 - 381
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy Eric Van CutsemFlorence JoulainJosep Tabernero Original Research Article 26 December 2015 Pages: 383 - 400
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib J. MateoV. MorenoL. R. Molife Original Research Article 12 May 2016 Pages: 401 - 415
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation Sohita Dhillon Adis Drug Evaluation 01 June 2016 Pages: 417 - 428
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy Evelyn DespierreIgnace VergoteAntonio Jimeno Erratum 08 April 2016 Pages: 429 - 429